ResearcherTianjin Medical University Cancer Institute and HospitalActive in the last 2 years
Libo Wang
Matched on ORCID iD 0000-0003-3745-9459; OpenAlex author ID A5060770488. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 11
2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 2 papers
Papers 5
- Targeting Mast Cell Activation and MIF-Mediated Remodelling Enhances Chemotherapy Response in Pancreatic Cancer. Co-author DOI 10.1002/advs.202509930↗
- Pharmacogenomics-based subtype decoded implications for risk stratification and immunotherapy in pancreatic adenocarcinoma. Co-author DOI 10.1186/s10020-024-01049-6↗
- Genome-scale CRISPR-Cas9 screening stratifies pancreatic cancer with distinct outcomes and immunotherapeutic efficacy. Co-author DOI 10.1016/j.cellsig.2023.110811↗
- Multi-omics landscape and clinical significance of a SMAD4-driven immune signature: Implications for risk stratification and frontline therapies in pancreatic … Co-author DOI 10.1016/j.csbj.2022.02.031↗
- Comprehensive machine-learning survival framework develops a consensus model in large-scale multicenter cohorts for pancreatic cancer. Co-author DOI 10.7554/elife.80150↗
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Xinwei Han · 4 shared papers, 2022–2025 · strength 0.71
- Paper Pharmacogenomics-based subtype decoded implications for risk stratification and immunotherapy in pancreatic adenocarcin… DOI 10.1186/s10020-024-01049-6↗
- Paper Genome-scale CRISPR-Cas9 screening stratifies pancreatic cancer with distinct outcomes and immunotherapeutic efficacy. DOI 10.1016/j.cellsig.2023.110811↗
- Paper Multi-omics landscape and clinical significance of a SMAD4-driven immune signature: Implications for risk stratificatio… DOI 10.1016/j.csbj.2022.02.031↗
- Yuyuan Zhang · 2 shared papers, 2022–2025 · strength 0.37
- Paper Pharmacogenomics-based subtype decoded implications for risk stratification and immunotherapy in pancreatic adenocarcin… DOI 10.1186/s10020-024-01049-6↗
- Paper Multi-omics landscape and clinical significance of a SMAD4-driven immune signature: Implications for risk stratificatio… DOI 10.1016/j.csbj.2022.02.031↗
- Rongtao Zhu · 2 shared papers, 2022 · strength 0.30
- Paper Multi-omics landscape and clinical significance of a SMAD4-driven immune signature: Implications for risk stratificatio… DOI 10.1016/j.csbj.2022.02.031↗
- Paper Comprehensive machine-learning survival framework develops a consensus model in large-scale multicenter cohorts for pan… DOI 10.7554/elife.80150↗
- Weijie Wang · 2 shared papers, 2022 · strength 0.30
- Paper Multi-omics landscape and clinical significance of a SMAD4-driven immune signature: Implications for risk stratificatio… DOI 10.1016/j.csbj.2022.02.031↗
- Paper Comprehensive machine-learning survival framework develops a consensus model in large-scale multicenter cohorts for pan… DOI 10.7554/elife.80150↗
- Yuling Sun · 2 shared papers, 2022 · strength 0.30
- Paper Multi-omics landscape and clinical significance of a SMAD4-driven immune signature: Implications for risk stratificatio… DOI 10.1016/j.csbj.2022.02.031↗
- Paper Comprehensive machine-learning survival framework develops a consensus model in large-scale multicenter cohorts for pan… DOI 10.7554/elife.80150↗
- Xing Zhou · 1 shared paper, 2025 · strength 0.22
- Peng Luo · 1 shared paper, 2025 · strength 0.22
- Yongjie Xie · 1 shared paper, 2025 · strength 0.20
- Qingxiao Fang · 1 shared paper, 2025 · strength 0.20
- Tianxing Zhou · 1 shared paper, 2025 · strength 0.20
- Jihui Hao · 1 shared paper, 2025 · strength 0.20
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.